Evidence map›Paper›PMID 41304156›Full record

ArticleMicroorganisms2025

Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant

Rosângela Siqueira Oliveira, Angela Pires Brandao, Fabiane Maria de Almeida Ferreira, Sonia Maria da Costa, Vera Lucia Maria Silva, Lucilaine Ferrazoli, Erica Chimara, Juliana Maira Watanabe Pinhata

Abstract read
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rosângela Siqueira OliveiraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.
Angela Pires BrandaoNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.ORCID 0000-0002-6036-9139
Fabiane Maria de Almeida FerreiraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.ORCID 0009-0005-8632-3736
Sonia Maria da CostaNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.
Vera Lucia Maria SilvaNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.
Lucilaine FerrazoliNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.
Erica ChimaraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.
Juliana Maira Watanabe PinhataNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil.ORCID 0000-0001-5758-6688

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 20/12585-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/16082-7
6 · The paper itself

Abstract

Drug-resistant tuberculosis (DR-TB) threatens global TB control. We investigated the prevalence and molecular characteristics of second-line drug resistance among rifampicin (RIF)- and/or isoniazid (INH)-resistant

Indexed as

gene sequencingline probe assaymultidrug-resistant tuberculosissecond-line anti-tuberculosis drugs

Identifiers

PMID41304156
PMCPMC12654774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.